Cannvas Announces International Expansion Strategy
Scalable Digital Education Platform Designed for Worldwide Use
TORONTO, Nov. 20, 2018 /CNW/ – Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC) (Frankfurt: 3CM), a leading digital education and business technology company in the cannabis space, is pleased to announce the launch of an international expansion strategy to broaden the reach of Cannvas.Me, its innovative digital education solution for the global medical cannabis community. With the legalization of medical and adult-use cannabis gaining traction in countries and states around the world, Cannvas is expanding Cannvas.Me beyond the borders of Canada to leading cannabis markets, beginning with Germany, one of the fastest-growing medical cannabis marketplaces in the world.
“We have had great success introducing our cannabis learning platform in Canada and look forward to educating others around the globe about the potential benefits of medical cannabis,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “The cannabis revolution continues to spread around the world with governments and regulators recognizing the lack of available information about cannabis and the need for better education. Building off our positive results in the Canadian marketplace and the global relationships we have developed, the opportunity has never been greater to significantly expand the reach of Cannvas.Me on an international basis.”
Less than a year ago, Cannvas became a reporting issuer with a mission to build a scalable, credible and accessible information resource for the medical cannabis marketplace. In the past 12 months the Company has listed on two stock exchanges, established partnerships with leading cannabis companies in Canada and launched its innovative Cannvas.Me digital cannabis education platform. Cannvas has grown to be recognized among the leaders in cannabis education in Canada, as the country has become a driving force in transforming the global cannabis market through its legalization of adult-use cannabis and the emergence of an influential and powerful industry.
Cannvas is also excited to announce its intention to expand into Germany, among the fastest-growing medical cannabis marketplaces in the world. The country has fully embraced medical cannabis as a legitimate health care product, with the support of its health care practitioners, pharmacists and insurance agencies.
“It’s no coincidence we have decided to expand the Cannvas brand into Europe to bring credible physician-backed cannabis education to the people of Germany as they grow accustomed to the ever-evolving medical cannabis landscape,” said Shawn Moniz, Chief Executive Officer at Cannvas MedTech. “With the support of Tech West, our team has spent the last year attending world-class technology trade shows and establishing a network of strategic contacts to ensure a smooth transition for Cannvas.Me when it expands outside Canada.”
Tech West Canada is known to provide early-stage tech companies like Cannvas with strategic guidance and business development support at an international level, and have been a valuable partner in introducing Cannvas to business growth opportunities around the world. The executive team at Cannvas recently returned from a successful trip to Portugal, having attended and presented at Web Summit 2018, the world’s largest technology conference. The team had the opportunity to meet with leading investors and companies from Europe and around the world and is following up with a number of promising leads. Over the past year, Cannvas has been part of a Canadian delegation that were showcased by Tech West at three international trade events: Web Summit in Lisbon, Portugal, CES in Los Angeles, California and Mobile World Congress in Barcelona, Spain.
As more countries around the world weigh the benefits of varying levels of decriminalization or legalization of medical or adult-use cannabis, the Cannvas team continues to meet with government agencies, policymakers and educators from all over the world to share the need for unbiased and physician-backed information contextualized to a specific country and its laws. Through the support the Company has received from its partnership with Tech West Canada, Cannvas hopes to leverage its Canadian success and bring high quality education to the world about the potential health benefits cannabis may provide.
Cannvas.Me is an unbiased educational resource for medicinal and adult-use cannabis users. It is a comprehensive solution for the global cannabis community offering innovative tools and physician-backed content to all audiences wishing to learn about health care through cannabis. The education platform utilizes machine-learning algorithms and artificial intelligence (AI) to contextualize and adapt as users navigate the website, to ensure a best-in-class experience for all using the most accurate and up-to-date information.
The Company also announces that it has issued an aggregate of 750,000 common shares (the “Shares“) of the Company at a deemed value of $0.315 per Share to a related party of the Company, pursuant to the achievement of certain milestones.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
SOURCE Cannvas MedTech Inc.
For further information: www.cannvasmedtech.com; Media Inquiries: firstname.lastname@example.org; Investor Relations, email@example.com, 1-800-489-0116